Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2024 10:00 ET | Source: HOPO Therapeutics, Inc.

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
October 22, 2024 01:30 ET | Source: CROSSJECT

Crossject annonce des progrès majeurs dans la fabrication de son traitement d’urgence ZEPIZURE®, pour la prise en charge des crises d’épilepsie, à l’approche du dépôt d’une demande d’autorisation d’utilisation d’urgence aux États-Unis.

Le lot de produits annoncé en juillet a permis de recueillir davantage de données de stabilité, qui au premier trimestre 2025 soutiendront directement la stabilité requise de six mois.Crossject...
October 22, 2024 01:30 ET | Source: CROSSJECT

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file...
October 22, 2024 00:30 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
October 17, 2024 08:07 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
September 12, 2024 16:56 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC

NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
September 12, 2024 08:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
July 18, 2024 01:30 ET | Source: CROSSJECT

Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®

Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
July 18, 2024 01:30 ET | Source: CROSSJECT

Crossject achieves key ZEPIZURE® manufacturing milestone

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
June 24, 2024 08:02 ET | Source: InflaRx N.V.

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...